Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?
unknown
📅 Published: 2025-10-14 15:09
📰 Source: Yahoo
📝 Words: 19
📝 Article Content
ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.
📄 Summary
ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.
Scraping Metadata:
Scraped At:
Unknown
Created At:
2025-10-20 09:46:12
Updated At:
2025-10-20 09:46:12
Scraping Job ID:
N/A
Stock Mentions:
ABBV - AbbVie Inc.
Relevance: N/A